Thymosin Alpha 1
Also known as: Tα1, Thymalfasin, Zadaxin
Thymosin alpha-1 is a 28-amino-acid immunomodulatory peptide. It has disease-specific human studies and international product use, but mixed sepsis results do not establish general immune optimization or longevity benefit.
Quick Facts
Peptide identity and international product context
Thymosin alpha-1, or Tα1, was originally isolated from thymus extracts associated with immune-cell maturation. Modern identity is a defined 28-residue N-acetylated peptide, not an assurance that every preparation is a thymic extract. It is marketed internationally as thymalfasin/Zadaxin, with approval in more than 35 countries for settings such as chronic hepatitis and immune or vaccine adjunct use. It is not FDA-approved in the United States. Thymopentin is a different five-residue peptide, not an alias.
Supporting references: approved drug in more than 35 countries; calf thymus extract; 28-amino-acid N-acetylated peptide.
Immune activity and clinical outcomes
Experimental and clinical immune measurements suggest effects on T-cell maturation/function, interferon-gamma and interleukin-2 signaling, and natural-killer-cell activity, partly involving Toll-like receptor pathways such as TLR9. These observations describe immunomodulation; improvement in an immune-cell marker does not by itself demonstrate fewer infections, reduced mortality or a benefit in healthy people.
Supporting references: TLR9 signaling.
Sources: [11]
Hepatitis and sepsis trials
Human research concerns specific immune conditions, with results depending on disease and design.
| Study | Participants | Findings |
|---|---|---|
| Randomized chronic hepatitis B study | 98 | After a 26-week course, complete virological response was 40.6% versus 9.4% without treatment (p=0.004); a 52-week course did not significantly outperform control |
| Earlier multicenter sepsis study | 361 | 28-day mortality 26.0% versus 35.0%, p=0.062: a borderline, nonsignificant suggestion |
| TESTS double-blind Phase 3 sepsis trial | 1,106 randomized; 1,089 analyzed across 22 Chinese centers | 28-day mortality 23.4% versus 24.1%; no clear mortality benefit or significant secondary/safety-outcome difference |
The original TESTS abstract reported HR 0.99 (95% CI 0.77–1.27; p=0.93). The published May 2025 correction retained on this site updated the primary HR to 0.97 (95% CI 0.76–1.24); the superseded estimate should not replace the correction. Participants received supervised subcutaneous treatment every 12 hours for seven days.
A separate hepatitis B trial reported modest viral/liver-marker effects. A 2025 meta-analysis of 11 sepsis trials gave a favorable pooled result, but benefit was not statistically demonstrated in its higher-quality or multicenter subgroups. A 2001 hepatitis B meta-analysis described delayed virological response, clearest around 12 months after treatment ended rather than during treatment. Neither pooled signals nor one negative trial resolves every indication.
Supporting references: randomized trial; trial; TESTS trial; modest effects on viral and liver markers; meta-analysis; meta-analysis; phase 3 TESTS sepsis trial.
Thymosin alpha-1 is not thymosin beta-4
Both were associated historically with thymosin fraction 5 from calf thymus, but their structures and actions differ. Tα1 is a 28-amino-acid immunomodulator acting on dendritic-cell and T-cell pathways. Thymosin beta-4 has 43 amino acids and is investigated for actin-related tissue repair and injury-site inflammatory pathways. Their clinical applications largely differ; evidence for one cannot be reassigned to the other.
Supporting references: thymosin fraction 5; 43-amino-acid peptide.
United States regulatory context
Thymosin alpha-1 is not FDA-approved for any US indication. In the September 2026 account, FDA lists its former Category 2 bulk-substance nomination as withdrawn; it is not on the 503A bulks list or in Category 1, so it is not eligible for 503A compounding under that described status. Withdrawal of a nomination is not a safety finding and does not change international Zadaxin approvals. A compounding category and approval of a finished medicine are separate matters. The 2026 advisory-meeting account did not identify a favorable review for Tα1.
Supporting references: FDA lists its Category 2 nomination as withdrawn.
Sources: [7]
Tolerability and unestablished wellness use
Clinical trials report a relatively low adverse-event burden: a hepatitis B study described mild reactions, commonly fluctuating liver enzymes, and TESTS found no significant safety-outcome difference from placebo. Those observations do not establish lifelong safety in other populations. FDA material on nominated-but-withdrawn preparations identifies immunogenicity, impurity and characterization concerns and inadequate safety information for proposed compounded products.
Disease-specific regimens do not establish a weekly wellness schedule, reliable anti-aging effect, vaccine enhancement for everyone or fewer training-related infections. The sepsis evidence does not validate stacks with epithalon, BPC-157, TB-500 or growth-hormone secretagogues; combinations need their own outcome and safety evidence.
Supporting references: hepatitis B trial.
Sources: [14]
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- pubmed.ncbi.nlm.nih.govPeptide identity and international product contextCited in: Peptide identity and international product context
- pubmed.ncbi.nlm.nih.govHepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- 10.1186/cc11932Hepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- 10.1136/bmj-2024-082583Hepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- 10.1111/j.1365-2893.2005.00633.xHepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- 10.3389/fcimb.2025.1673959Hepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- fda.govUnited States regulatory contextCited in: United States regulatory context
- pubmed.ncbi.nlm.nih.govThymosin alpha-1 is not thymosin beta-4Cited in: Thymosin alpha-1 is not thymosin beta-4
- pubmed.ncbi.nlm.nih.govPeptide identity and international product contextCited in: Peptide identity and international product context
- pubmed.ncbi.nlm.nih.govPeptide identity and international product contextCited in: Peptide identity and international product context
- pubmed.ncbi.nlm.nih.govImmune activity and clinical outcomesCited in: Immune activity and clinical outcomes
- pubmed.ncbi.nlm.nih.govThymosin alpha-1 is not thymosin beta-4Cited in: Thymosin alpha-1 is not thymosin beta-4
- pubmed.ncbi.nlm.nih.govHepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- pubmed.ncbi.nlm.nih.govTolerability and unestablished wellness useCited in: Tolerability and unestablished wellness use
- pubmed.ncbi.nlm.nih.govHepatitis and sepsis trialsCited in: Hepatitis and sepsis trials
- pubmed.ncbi.nlm.nih.gov — additional reading
- www.ncbi.nlm.nih.gov — additional reading
- pmc.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
Frequently Asked Questions About Thymosin Alpha 1
No. Thymopentin is a distinct pentapeptide; thymosin alpha-1 has 28 amino acids.
No clear benefit was found. Its corrected primary hazard ratio was 0.97, with a 95% confidence interval of 0.76–1.24.
No. Disease-specific research regimens do not establish a universal wellness dose or long-term combination protocol.
No. The September 2026 account identifies no FDA-approved indication, while thymalfasin/Zadaxin is approved in more than 35 other countries. US compounding status is separate from international product approval.
Tα1 is a 28-residue N-acetylated immune-modulating peptide. Full-length thymosin beta-4 is a 43-residue peptide associated with actin and repair pathways. Shared discovery history does not make their evidence or uses interchangeable.
Timing depends on the indication. In hepatitis B research, virological response could increase after therapy stopped and was clearest around 12 months later in a 2001 meta-analysis. This cannot supply a generic wellness onset.
Reported burden was low in the cited disease trials: mild hepatitis B reactions often involved liver-enzyme fluctuation, and TESTS found no significant safety-outcome difference. This does not establish every preparation’s or long-term use’s safety.
FDA lists the prior Category 2 nomination as withdrawn. That is not a finding of safety or inclusion in the 503A bulks list or Category 1. The described September 2026 status does not permit 503A compounding.
No. FDA-approved medicines, qualifying patient-specific compounded medicines and research chemicals have distinct requirements. A supplier’s listing is not evidence that Tα1 qualifies for the approved or 503A pathway.
No legally recognized US over-the-counter Tα1 formulation is identified in the account, and the stated 503A status does not permit preparation by that pathway. International prescription approvals are a separate context.
The multicenter Phase 3 study randomized 1,106 adults and analyzed 1,089. Mortality at 28 days was 23.4% versus 24.1% with placebo, with no clear benefit. Use the corrected HR 0.97 (95% CI 0.76–1.24), rather than the original abstract’s superseded 0.99 estimate.
Related Peptides
Continue exploring Thymosin Alpha 1
- BPC-157 vs Thymosin Alpha-1: Gut and Immune Research [2026]Comparison
- Peptides for Immune Support: Thymosin Alpha-1, LL-37 & MoreGuide
- TB-500 vs Thymosin Alpha-1: Repair and Immune Research [2026]Comparison
- Thymosin Alpha-1 Benefits: Immune Support & Research [2026]Guide
- Thymosin Alpha-1 Dosage: Protocols & Administration [2026]Guide
- Thymosin Alpha-1: Immune Modulation, Uses, and Clinical EvidenceGuide
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.